Association of race/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US
Importance Sodium-glucose cotransporter 2 (SGLT2) inhibitors significantly reduce deaths
from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney …
from cardiovascular conditions, hospitalizations for heart failure, and progression of kidney …
Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the Veterans Health …
Importance Novel therapies for type 2 diabetes can reduce the risk of cardiovascular
disease and chronic kidney disease progression. The equitability of these agents' …
disease and chronic kidney disease progression. The equitability of these agents' …
Utilization rates of SGLT2 inhibitors and GLP-1 receptor agonists and their facility-level variation among patients with atherosclerotic cardiovascular disease and type …
D Mahtta, DJ Ramsey, MT Lee, L Chen… - Diabetes …, 2022 - Am Diabetes Assoc
OBJECTIVE There is mounting evidence regarding the cardiovascular benefits of sodium–
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists …
glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists …
Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study
Background Randomized trials demonstrated a lower risk of cardiovascular (CV) events with
sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at …
sodium-glucose cotransporter-2 inhibitors (SGLT-2i) in patients with type 2 diabetes (T2D) at …
Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcomes in patients with type 2 diabetes and other risk factors for cardiovascular disease …
Importance The cardiovascular outcome in selected populations when sodium-glucose
cotransporter 2 inhibitors (SGLT2-Is) are emerging as standard therapy is not clearly …
cotransporter 2 inhibitors (SGLT2-Is) are emerging as standard therapy is not clearly …
Patterns of prescribing sodium-glucose cotransporter-2 inhibitors for Medicare beneficiaries in the United States
Background: Evidence from large randomized clinical trials supports the benefit of SGLT2i
(sodium-glucose cotransporter-2 inhibitors) to improve cardiovascular and kidney outcomes …
(sodium-glucose cotransporter-2 inhibitors) to improve cardiovascular and kidney outcomes …
National trends in use of sodium‐glucose cotransporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists by cardiologists and other specialties, 2015 to …
Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) and glucagon‐like
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
peptide‐1 receptor agonists (GLP‐1RAs) mitigate cardiovascular risk in individuals with type …
Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
Aims To determine the association between cardiovascular diseases (CVD) and SGLT2
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …
inhibitors compared to sulfonylureas and dipeptidyl peptidase‐4 (DPP4) inhibitors and to …
Comparative effectiveness of sodium-glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes
Importance In the treatment of type 2 diabetes, evidence of the comparative effectiveness of
sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas—the second most …
sodium-glucose cotransporter 2 (SGLT2) inhibitors vs sulfonylureas—the second most …
Incident heart failure, arrhythmias and cardiovascular outcomes with sodium‐glucose cotransporter 2 (SGLT2) inhibitor use in patients with diabetes: Insights from a …
AM Fawzy, JM Rivera‐Caravaca… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To investigate the impact of sodium‐glucose cotransporter 2 (SGLT2) inhibitors on the
risk of incident heart failure and adverse cardiovascular outcomes. Methods All patients with …
risk of incident heart failure and adverse cardiovascular outcomes. Methods All patients with …
相关搜索
- inhibitor use patients with diabetes
- inhibitor use glucose cotransporter
- inhibitor use race ethnicity
- race ethnicity sodium glucose
- patients with diabetes glucose cotransporter
- patients with diabetes race ethnicity
- socioeconomic status sodium glucose
- socioeconomic status race ethnicity
- inhibitor use socioeconomic status
- patients with diabetes socioeconomic status
- sglt2 inhibitors association of race
- sulfonylureas in patients sodium glucose
- inhibitors in patients cardiovascular outcomes
- glucose cotransporter cardiovascular outcomes
- cardiovascular disease sodium glucose
- meta analysis sodium glucose